重新评估降钙素原指导脓毒症危重患者抗生素治疗:ADAPT-Sepsis 试验启示
本文解读 ADAPT-Sepsis 试验:采用隐蔽干预、稳健抗菌药物管理与降钙素原(PCT)与 C 反应蛋白(CRP)头对头比较,PCT 指导减少抗生素使用且未显著影响死亡率,CRP 指导无获益;但算法依从性欠佳,PCT 组抗生素疗程绝对缩短仅 1 天。
要点
- PCT 指导减少抗生素使用,未显著影响死亡率;CRP 指导无获益。
- PCT 组抗生素疗程绝对缩短仅 1 天,算法依从性欠佳。
- 固定短疗程渐成标准,PCT 在 ICU 的效用可能下降。
核心结论
- PCT 指导的抗生素管理可减少抗生素使用且未显著影响死亡率,但疗程绝对缩短仅 1 天,算法依从性欠佳,随着固定短疗程普及其 ICU 效用可能下降。
研究设计与样本
- ADAPT-Sepsis 为随机试验,采用隐蔽干预、稳健抗菌药物管理,并进行 PCT 与 CRP 的头对头比较。
主要发现
- PCT 指导组减少抗生素使用,未显著影响死亡率。
- CRP 指导组未显示获益。
- 算法依从性欠佳,PCT 组抗生素疗程绝对缩短仅 1 天。
临床怎么用
- 应将 PCT 及其他生物标志物嵌入多层面的抗菌药物管理策略,并解决临床医生信任与实施障碍。
- 未来研究应评估在脓毒症诊疗路径更早期(尤其急诊科)使用生物标志物能否提高诊断准确性并改善患者结局。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized trials of procalcitonin-guided algorithms to discontinue antibiotics in critically ill patients with sepsis report reduced antibiotic duration and possible mortality benefit. However, open-label trial designs, inconsistent algorithm adherence, and unclear stewardship practices have limited confidence in procalcitonin's benefit. The ADAPT-Sepsis trial addressed several of these gaps through a concealed intervention, robust stewardship, and head-to-head comparison with C-reactive protein (CRP). Procalcitonin-guided care reduced antibiotic use without significantly impacting mortality, although CRP-guided care showed no benefit. However, algorithm adherence was suboptimal, and the absolute reduction in antibiotic duration with procalcitonin was only 1 day. As shorter fixed-duration therapy becomes standard, procalcitonin's utility in the intensive care unit may decline. Embedding procalcitonin and other biomarkers into multifaceted stewardship strategies, and addressing barriers to clinician trust and implementation, is essential. Future research should also evaluate whether biomarker use earlier in the sepsis care pathway, particularly in Emergency Departments, can improve diagnostic accuracy and enhance patient outcomes.
引用
- Gupta S, Klompas M, Rhee C, et al. Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial. Clin Infect Dis. 2026. PMID: 40579227. doi:10.1093/cid/ciaf336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。